VolitionRx Limited (NYSE: VNRX) advanced its Nu.Q® NETs platform toward commercialization on July 30, 2026, citing consistent international clinical data that positions the technology as a potential game changer in sepsis management. The multi-national epigenetics company identified a Total Addressable Market (TAM) of approximately $3.8 billion on an annualized basis, driven by the need for accurate differentiation between sepsis and non-infectious systemic inflammation. This development signals a shift from research to potential revenue generation as Volition engages with major diagnostic partners to scale its nucleosome quantification technology.

The company released a comprehensive update detailing the scientific evidence amassed for Nu.Q® NETs, alongside a video featuring Critical Care Lead Dr Andrew Retter. The findings indicate that Nu.Q® H3.1 accurately distinguishes sepsis from other inflammatory conditions and correlates highly with disease severity. Professor Djillali Annane of IHU SEPSIS noted that the consistency of data across different countries and sepsis types provides significant prognostic utility for outcomes such as organ failure and mortality.

Commercial Strategy and Market Opportunity

Gael Forterre, Chief Commercial Officer at Volition, confirmed that the company is in active discussions with several large diagnostic companies to accelerate the development of Nu.Q® NETs. These partnerships aim to leverage the test’s potential use cases within a $3.8 billion annualized market. The strategy focuses on integrating Nu.Q® NETs into hospital settings to modify patient trajectories through early detection of elevated H3.1 nucleosome levels.

Clinical Validation and Scientific Evidence

Dr Andrew Retter emphasized that a significant body of scientific and clinical evidence now supports the use of Volition’s Nu.Q® NETs assay in diseases associated with NETosis. Most of these papers have been peer-reviewed and published. The technology offers a simple, low-cost, and accessible test to detect diseases linked to elevated NETs, which can lead to tissue damage, organ failure, and death if left untreated.

Professor Annane highlighted that Nu.Q® H3.1 provides new information above standard organ failure scores such as APACHE II and SOFA scores. This additional layer of data allows for more precise treatment strategies, potentially improving patient survival rates and the quality of life for survivors. The company’s research centers in Belgium, the U.S., and London continue to drive these advancements.

What the Numbers Show

The valuation of the sepsis biomarker market at $3.8 billion underscores the high stakes for Volition’s commercialization efforts. Unlike general inflammatory markers, Nu.Q® H3.1’s ability to distinguish infectious from non-infectious causes addresses a critical gap in critical care diagnostics. The consistency of data across multiple international studies reduces the risk of false positives, a key barrier to adoption in hospital settings. Success in securing licensing agreements will depend on demonstrating cost-effectiveness and improved patient outcomes compared to existing standards.

VolitionRx Limited announced new clinical data demonstrating the prognostic value of its Nu.Q Cancer Assay for newly diagnosed lung cancer patients. The study indicates the test can help clinicians identify patient outcomes and personalize treatment selection. This development is significant for the company's commercialization efforts in the human cancer field.

The clinical paper, titled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence," was developed with researchers at Hospices Civils de Lyon. The study found that plasma levels of the Nu.Q Cancer assay H3K27Me3 were associated with cancer stage. Patients with levels below the optimal cut-off showed significantly better mean survival compared to those with higher concentrations.

Clinical Study Findings

The research highlights the test's ability to enhance precision in patient management. Key findings from the study include:

• Risk Stratification: A Cox Proportional Hazards model integrating baseline H3K27Me3-nucleosome concentrations with clinical covariates enabled stratification of patients into low and high-risk mortality groups at diagnosis.
• Survival Prediction: The model facilitates the prediction of patient-level survival probabilities over a timeline of up to 30 months.
• Actionable Insights: The test provides valuable information for patients who are ctDNA-negative and lack detectable actionable mutations.

Dr. Andrew Retter, Medical Consultant at Volition, emphasized the test's potential to refine patient care. He stated that measuring methylated nucleosome biomarker levels at Non-Small Cell Lung Cancer diagnosis can offer insights into survival and progression-free survival.

Commercialization and Reimbursement

Volition is advancing the Nu.Q Cancer Test toward routine clinical use. Frederic Wuilque, Vice President, Global Products, confirmed that clinical certification at Hospices Civils de Lyon is complete. The company is working towards submitting a reimbursement dossier under the "Innovative Procedures Outside the Nomenclature" framework in the coming months.

Gael Forterre, Chief Commercial Officer, noted that France represents the starting point for the company's commercial strategy. Volition is discussing the test with hospital networks in other countries and exploring licensing opportunities with third-party collaborators.